SCHEMBL1140927

SCHEMBL1140927

Nc1nc2ncccc2c2[nH]cnc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.42
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
PDPK1 O15530 1/20 0.39
GDA Q9Y2T3 1/20 0.39
PARP1 P09874 1/20 0.38
BRD4 O60885 1/20 0.38
ACHE P22303 2/20 0.38
NUDT1 P36639 1/20 0.38
PI4KA P42356 2/20 0.36
PI4K2B Q8TCG2 2/20 0.36
PI4K2A Q9BTU6 2/20 0.36
PI4KB Q9UBF8 2/20 0.36
LMNA P02545 1/20 0.36
DRD3 P35462 1/20 0.36
XDH P47989 1/20 0.36
LRRK2 Q5S007 1/20 0.36
HCAR2 Q8TDS4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29809376 1.00 DHFR (0.42) DHFRPDE4APDE4BPDE4CPDE4D
SCHEMBL212131 0.77 TLR7 (0.44) PDE4DPDPK1PARP1ACHENUDT1
SCHEMBL29694218 0.77 TLR7 (0.44) PDE4DPDPK1PARP1ACHENUDT1
SCHEMBL1007376 0.75 DHFR (0.53) DHFRPARP1ACHENUDT1LMNA
SCHEMBL30413516 0.75 PRMT5 (0.42) DHFRPDE4APDE4BPDE4CPDE4D
SCHEMBL311681 0.75 PRMT5 (0.42) DHFRPDE4APDE4BPDE4CPDE4D
Hydrochloric Acid SCHEMBL5523405 0.75 RAB9A (0.44) PDE4DPDPK1PARP1ACHENUDT1
SCHEMBL4377817 0.75 DHFR (0.40) DHFRPARP1ACHENUDT1LMNA
Hydrochloric Acid SCHEMBL10587438 0.74 ALDH1A1 (0.46) PDE4DPDPK1PARP1ACHENUDT1
SCHEMBL28312743 0.73 TLR7 (0.44) PDE4DACHENUDT1LMNAADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3802536-B1 N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS 3M INNOVATIVE PROPERTIES CO (US) 2022-07-13 EP disclosed
US-10071156-B2 Aqueous gel formulations containing immune response modifiers 3M INNOVATIVE PROPERTIES COMPANY (US) 2018-09-11 US disclosed
US-20180222906-A1 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2018-08-09 US disclosed
US-9938275-B2 Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2018-04-10 US disclosed
US-20170129891-A1 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES CO (US) 2017-05-11 US disclosed
US-9550773-B2 Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2017-01-24 US disclosed
EP-1844201-B1 AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS 3M INNOVATIVE PROPERTIES CO (US) 2016-08-24 EP disclosed
EP-1765348-B1 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES 3M INNOVATIVE PROPERTIES CO (US) 2016-08-03 EP disclosed
US-20160101173-A1 AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS 3M INNOVATIVE PROPERTIES CO (US) 2016-04-14 US disclosed
US-9248127-B2 Aqueous gel formulations containing immune response modifiers 3M INNOVATIVE PROPERTIES COMPANY (US) 2016-02-02 US disclosed
US-6518280-B2 Antiviral and antitumor properties; immunomodulators and for inducing cytokine biosynthesis in animals 3M INNOVATIVE PROPERTIES COMPANY 2003-02-11 US disclosed
US-6514985-B1 Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; exhibit antiviral and antitumor properties 3M INNOVATIVE PROPERTIES COMPANY 2003-02-04 US disclosed
US-20020193396-A1 Sulfonamido ether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2002-12-19 US disclosed
US-20020173654-A1 Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US disclosed
US-20020173653-A1 Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US disclosed
US-20020173655-A1 Thioether substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY 2002-11-21 US disclosed
WO-2002046192-A2 THIOETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed
WO-2002046191-A2 UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed
WO-2002046188-A2 AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2002-06-13 WO disclosed
US-6194425-B1 VIRICIDES, ANTITUMOR AGENTS 3M INNOVATIVE PROPERTIES COMPANY 2001-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180222906-A1 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES IL2, IFNG, IL4 DHFR 186/4885PDE4A 581/4885PDE4B 899/4885
US-10071156-B2 Aqueous gel formulations containing immune response modifiers IFNG, ICOS, IL4 DHFR 269/4885PDE4A 557/4885PDE4B 817/4885
US-20020173653-A1 Imidazonaphthyridines IFNG, IRF3, IFNAR1 DHFR 119/4885PDE4A 1035/4885PDE4B 1885/4885
US-20020173654-A1 Imidazonaphthyridines IFNG, IRF3, IFNAR1 DHFR 119/4885PDE4A 1035/4885PDE4B 1885/4885
US-20160101173-A1 AQUEOUS GEL FORMULATIONS CONTAINING IMMUNE RESPONSE MODIFIERS IFNG, ICOS, IL4 DHFR 269/4885PDE4A 557/4885PDE4B 817/4885
US-20170129891-A1 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES IL2, IFNG, IL4 DHFR 186/4885PDE4A 581/4885PDE4B 899/4885
US-20020173655-A1 Thioether substituted imidazoquinolines IFNG, IRF3, IL2 DHFR 434/4885PDE4A 3061/4885PDE4B 4007/4885
US-20020193396-A1 Sulfonamido ether substituted imidazoquinolines IFNG, IRF3, IL2 DHFR 784/4885PDE4A 2648/4885PDE4B 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.